Therapy Protocol ALL SCT BFM International-open, Multicenter, Controlled, Prospective Study for Therapy and Therapy Optimisation in Patients With Acute Lymphoblastic Leukemia (ALL) and an Indication for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Therapy Protocol ALL SCT BFM International-open, Multicenter, Controlled, Prospective Study for Therapy and Therapy Optimisation in Patients With Acute Lymphoblastic Leukemia (ALL) and an Indication for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). To evaluate the efficacy of HSCT from mismatched family or unrelated donors (MMD) as compared to HSCT from MSD/MD. To determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. To prospectively evaluate and compare the incidence of acute and chronic GvHD after HSCT from MSD, from MD and from MMD.
Inclusion Criteria:
all patients with ALL (except for patients with B-ALL) who fulfil the following criteria:
age at time of initial diagnosis or relapse diagnosis, respectively
≤18 years
indication for allogeneic HSCT
complete remission (CR) is achieved before SCT
written consent of the parents (legal guardian) and, if indicated, the minor patient via "Informed Consent Form"
no pregnancy
no secondary malignancy
no previous HSCT
HSCT is performed in a study participating centre.
Exclusion Criteria:
Petach Tikvah, 49202, Israel